Intelligent Bio Solutions Inc. Expands Fingerprint Drug Testing in Scandinavia Through Spjotgard Partnership
June 25th, 2025 1:20 PM
By: FisherVista
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is expanding its non-invasive fingerprint drug testing technology across Scandinavia, marking a significant step forward in workplace and public safety drug screening.

Intelligent Bio Solutions Inc. (NASDAQ: INBS), a leader in non-invasive drug screening technology, is making strides in Scandinavia through its partnership with Spjotgard, a key distributor in the region. This collaboration is facilitating the widespread adoption of INBS's innovative fingerprint-based Drug Screening System across Sweden, Norway, and Denmark, with growing interest in Finland. The technology represents a leap forward in drug testing, offering a hygienic, quick, and less invasive alternative to traditional methods such as urine and saliva tests, with results available in under 10 minutes.
The significance of this expansion cannot be overstated. The fingerprint drug testing system is gaining traction in critical sectors including logistics, education, and criminal justice, where rapid and reliable drug screening is essential. Spjotgard's established presence and strategic partnerships in Scandinavia are instrumental in scaling INBS's operations in Northern Europe, promising to enhance workplace safety and public health monitoring across the region.
This development is particularly important as it addresses the growing need for efficient and non-invasive drug screening solutions in various industries. The ability to quickly and accurately detect drug use without the discomfort and privacy concerns associated with traditional methods could revolutionize how employers and authorities approach drug testing. For more information on Intelligent Bio Solutions Inc. and its groundbreaking technology, visit https://ibn.fm/meqb1.
Source Statement
This news article relied primarily on a press release disributed by InvestorBrandNetwork (IBN). You can read the source press release here,
